Do you know an EU broker where it is possible to buy it?

Which Platform do you use to buy itoco stocks?

What the hell it decreases every day!! I hope it Will change on August 4th

What does that mean endless option?

When a company posts earnings, the reports are intensely examined by investors and analysts alike. Earnings are important because they can give insight into the profitability of a company. Covering Street analysts are looking for Orexigen Therapeutics, Inc. (NASDAQ:OREX) to report quarterly EPS of $-0.15. The company is next expected to publish earnings on or around 2016-08-04 for the period ending 2016-06-30. In the same quarter last year, the company posted EPS of $-0.18. The company most recently posted quarterly earnings per share of $-0.15. Leading up to the earnings report, the Zacks Research consensus using polled analysts was $-0.1. The gap in the numbers was $-0.05 which created a surprise factor of -50%. Surprise factors are important to view as a company releases earnings. Surprise factors may create significant stock price movements after the release.

Covering analysts often adjust projections before and after the earnings period. Presently, analysts polled by Zacks Research have a mean target price of $1.025 on shares. This target is including 4 different analysts taken into consideration by Zacks Research. Analyst standpoints may vary on where they anticipate the stock heading in the future. Out of all the polled analysts, the most bullish estimate has the stock hitting 2 in the next year. The analyst with the low end target price views shares going to $0.5 within the same period. Zacks Research compiles analyst ratings using a scale that spans from 1 to 5. If the company has a ratings score of 1, this would indicate a Strong Buy. If the company has a 5 rating, this would signify a Strong Sell. Combining all the ratings on Orexigen Therapeutics, Inc. (NASDAQ:OREX), the present mean is sitting at 3.2.

This is strange there are no more followers here

Orexigen Therapeutics (NASDAQ:OREX) last issued its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.17) by $0.02. During the same quarter in the prior year, the firm posted ($0.14) earnings per share. The business earned $5 million during the quarter, compared to analyst estimates of $7.78 million. Orexigen Therapeutics’s revenue for the quarter was up 16.3% compared to the same quarter last year. Analysts anticipate that Orexigen Therapeutics, Inc. will post ($0.50) EPS for the current fiscal year.
OREX has been the subject of several recent analyst reports. Zacks Investment Research reaffirmed a “buy” rating and set a $2.25 price objective on shares of Orexigen Therapeutics in a research report on Sunday, January 31st. Leerink Swann cut shares of Orexigen Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $4.50 to $2.00 in a research report on Tuesday, February 23rd. RBC Capital cut shares of Orexigen Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $5.00 to $1.00 in a research report on Monday, February 29th. JPMorgan Chase & Co. cut shares of Orexigen Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, February 29th. Finally, Piper Jaffray decreased their price objective on shares of Orexigen Therapeutics from $11.00 to $5.00 and set an “overweight” rating for the company in a research report on Monday, February 29th. One analyst has rated the stock with a sell rating and nine have given a hold rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $2.61.
Orexigen Therapeutics, Inc (NASDAQ:OREX) is a biopharmaceutical company. The Company is focused on the development of pharmaceutical product candidates for the treatment of obesity. The Company’s product is Contrave, a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Sure..

"We believe that by successfully executing on our plans, Orexigen can achieve profitability beginning in full year 2019 and that the capital we raised in March in connection with the Contrave acquisition will be sufficient to get us there," Narachi said.

How could it be it has so decreased these last months?

What is the OS? Are they still diluting right now?

Should they stop diluting???

Great info! I hope it is tangible!! It Should be Nice to receive pictures

Sorry for my basic english... So that means we are very close to the end?

Do I understand correctly?? Is it going to take 2 More years to see the manufactory fully operational ???

Building a plant of this magnitude would normally take up to 4 years to construct. Hemp, Inc. is looking at accomplishing this in about 2 years. (See recent video updates)

http://hempinc.com/build-industrial-hemp-fiber-processing-plant/

When will It increase??? When is It supposed to be legal? When will the factory be operationnal??

Again in the red... Incredible...

From'a technical point of view, It seems impossible to break ma200

There is unfortunately only a trend here

Future Will tell

What is your timing? From a technical point of view, it goes worst days after days

Even the potential reclassification does not impact the share value, how could it be?

I look forward reading DEA decision!!

Has someone seen L2? Not looking great...

If they are operating with kenaf, they could switch quickly with Hemp... Counting on 3 harvest a year, it could be fast. Anyway, there is a point I don't understand with you. How could it be you are trying to destroy this start up? What is your objective Jesus ?

You forget it is possible to harvest several times a year...

Still no information regarding the reclassification which has to occur before end of June?
No date?
No information?

So no reason to demonstrate your statement ???

Could you justify this by analysis/thinking/advice?

I don't think it means an explosion to the sky but simply a long reversal to higher prices... But combined with a national legalization (which could take place before June 30), we Should touch the sky;)

Has someone News regarding the national legalization which Should take place before June 30th 2016? Any timing?

A flat starting trading day

Only shorters / profit takers today!!

How could it be it decreases when substance is announced? Totally illogical

It can only be positive

Could we estimate the potential revenues of this first set of production?

If its is true, this is really nice because we only need substance here!!!

They are just stealing out money